Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod 3.75% for subclinical actinic keratosis
NCT04842422Phase 4Completed
- Sponsor
- Medical University of Graz
- Start
- Apr 2021
- Primary completion
- Aug 2021
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of imiquimod in actinic keratosis (AK), sponsored by Medical University of Graz. Started Apr 2021; status: completed.
02
Drugs
imiquimod
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT04842422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04842422.